As of February 23, 2024, analysts have differing opinions on the price target for Amgen (NASDAQ: AMGN). Here are some of the price targets provided by various analysts:
– Morgan Stanley has an Equal-Weight rating with a price target of $278.
– Oppenheimer upgraded its rating to Outperform with a price target of $350.
– Goldman Sachs maintains a Buy rating with a price target of $350.
– UBS has a Neutral rating targeting a price of $314.
– RBC Capital has an Outperform rating targeting a price of $329.
On average, the price target proposed by 5 industry analysts over the past month is $324.2. These diverse price targets indicate varying perspectives on Amgen’s future performance and market value.
Amgen Inc. (AMGN) Shows Strong Price Momentum on February 23, 2024
On February 23, 2024, Amgen Inc. (AMGN) showed positive price momentum as it traded in the middle of its 52-week range and above its 200-day simple moving average. The stock opened at $286.57, $1.39 higher than its previous close, indicating a strong start to the trading day.
Throughout the day, AMGN shares continued to show strength as the price increased by $3.64, representing a 1.28% rise since the market last closed. This increase in price demonstrates investor confidence in the company and its potential for growth.
Amgen Inc. is a biotechnology company known for its innovative therapies in areas such as oncology, nephrology, and cardiovascular disease. With a strong pipeline of products and a solid track record of success, AMGN has been a favorite among investors looking for exposure to the healthcare sector.
Investors who have been following AMGN closely may have been pleased with the stock’s performance on February 23, 2024. The positive price momentum, coupled with the stock trading above its 200-day moving average, suggests that AMGN may continue to see gains in the near future.
Amgen Inc. (AMGN) Reports Financial Performance for 2023: Revenue Up, Net Income Flat
On February 23, 2024, Amgen Inc. (AMGN) reported its financial performance for the past year and the fourth quarter. According to data from CNN Money, the biotechnology company generated a total revenue of $28.01 billion over the past year, which represents a 7.35% increase compared to the previous year. However, the total revenue for the fourth quarter was $8.14 billion, which remained flat compared to the previous quarter.
In terms of net income, Amgen reported a total of $6.72 billion for the past year, which was the same as the previous year. The net income for the fourth quarter was $767.00 million, which also remained flat compared to the previous quarter.
Earnings per share (EPS) for Amgen stood at $12.49 for the past year, showing a 3.09% increase compared to the previous year. However, the EPS for the fourth quarter was $1.42, which represented a significant decrease of 55.83% compared to the previous quarter.
Overall, Amgen’s financial performance on February 23, 2024, showed a mixed picture. Investors and analysts will be closely monitoring Amgen’s future performance to see if the company can sustain its growth and profitability in the coming quarters.
